Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 14/20 | 0.78 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.78 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.78 |
| ▸ | TMPRSS4 | Q9NRS4 | 6/20 | 0.71 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.66 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.61 |
| ▸ | FADS1 | O60427 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330366 | 0.89 | P2RX1 (0.78) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL11932152 | 0.88 | P2RX1 (1.00) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL13189691 | 0.87 | TMPRSS4 (0.76) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL11683279 | 0.84 | P2RX1 (0.82) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL538439 | 0.83 | TMPRSS4 (1.00) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL3860231 | 0.83 | P2RX1 (0.78) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL11932156 | 0.83 | P2RX1 (0.78) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL13812565 | 0.83 | P2RX1 (0.78) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL2700843 | 0.82 | P2RX1 (1.00) | P2RX1FADS1 | |
| SCHEMBL330581 | 0.82 | P2RX1 (0.76) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130324555-A1 | Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals | WOOD RICHARD DELAREY (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD D (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD D (US) | 2013-06-13 | — | — | US | disclosed |
| US-8211882-B2 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211882-B2 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY (US) | 2012-07-03 | — | — | US | disclosed |
| WO-2010101648-A1 | GLUTAMATE RECEPTOR MODULATORS AND THERAPEUTIC AGENTS | WOOD RICHARD D (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY | 2009-09-24 | — | — | US | disclosed |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | GRM5, GRM1, GRIK5 | P2RX1 542/4885P2RX4 611/4885P2RX7 913/4885 |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | GRM5, GRM1, GRIK5 | P2RX1 365/4885P2RX4 388/4885P2RX7 660/4885 |
| US-20130324555-A1 | Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals | PIGS, ASAH2, ASAH1 | P2RX1 827/4885P2RX4 1017/4885P2RX7 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.